Precigen, Inc. (NASDAQ:PGEN)

Stock Price: $1.86
-0.075 (-3.89%)
Updated Feb 7, 2023 08:59 PM GMT+0000
Featured app
eToro
Invest now
<p>79% of retail CFD accounts lose money</p>
Overview
Financials
Statistics
Profile
Chart
Market Cap 465.62M
Revenue 75.88M
Gross Profit 40.46M
Shares Out 251.01M
EPS (ttm) 0.1273
PE Ratio 19.0284
Forward PE -3.7295
Dividend Rate (ttm) 0.0000
Dividend Yield 0.0000
Trading Day Feb 7
Last Price $1.86
Previous Close $1.93
Change ($) -0.075
Change (%) -3.89%
Day's Open 1.96
Day's Range Market Closed
Day's Volume 2.35M
52 Week Range 1.12 - 2.9

About Precigen, Inc.

Precigen is a dedicated discovery and clinical stage biopharmaceutical company advancing the next generation of gene and cell therapies using precision technology to target the most urgent and intractable diseases in its core therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. The Company's technologies enable to find innovative solutions for affordable biotherapeutics in a controlled manner. Precigen operates as an innovation engine progressing a preclinical and clinical pipeline of well-differentiated unique therapies toward clinical proof-of-concept and commercialization.

News

No news found.

Quick info

Country
United States
Industry
Research and Development in Biotechnology
Sector
Professional, Scientific, and Technical Services
Employees
484
CEO
Helen Sabzevari
Address
20374 Seneca Meadows Parkway
Germantown
Maryland
20876
Phone
13015569900
Website
precigen.com
Ticker Symbol
PGEN
Reporting Currency
USD